Scholarlink

Purpose <p>This study aimed to develop and validate a personalized prognostic model for patients with newly diagnosed with acute myeloid leukemia (AML) receiving intensive cytarabine- and anthracycline-based chemotherapy.</p> Methods <p>&#xa0;We retrospectively analyzed 161 patients treated at a single center and externally validated the model in 184 patients from two institutions.</p> Results <p>Using LASSO Cox regression, nine readily available clinical variables (age, sex, performance status, history of diabetes, respiratory disease, prior myelodysplastic syndrome or myeloproliferative neoplasm, serum albumin level, uric acid level, and adverse cytogenetic risk) were selected to construct a nomogram. The model demonstrated good discrimination of overall survival, with a concordance index of 0.721 and 0.678 in the training and validation cohorts, respectively. Calibration plots showed strong agreement between the predicted and observed outcomes. Based on the nomogram scores, the patients were stratified into three risk groups, with 3-year overall survival rates of 84.1%, 57.2%, and 11.9% in the good, intermediate, and poor-risk groups, respectively. To enhance clinical accessibility, an online tool was developed for use in real-world settings.</p> Conclusion <p>This nomogram integrates disease- and patient-related factors and allows for individualized prognostic assessment. This may support clinical assessment through personalized risk evaluation in AML patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Personalized multivariable clinical prognostic model for patients with acute myeloid leukemia receiving intensive chemotherapy

  • 期刊论文

  • 发表日期：

    2026年5月12日

查看全文
  • Kengo Katsuki,
  • Takuya Miyazaki,
  • Moka Komaki,
  • Yusuke Saigusa,
  • Takayoshi Tachibana,
  • Takayuki Sakuma,
  • Kodai Hasegawa,
  • Natsuki Hirose,
  • Masahiro Akimoto,
  • Akihiko Izumi,
  • Takuma Ohashi,
  • Ayako Matsumura,
  • Taisei Suzuki,
  • Yoshimi Ishii,
  • Yuki Nakajima,
  • Maki Hagihara,
  • Masatsugu Tanaka,
  • Shin Fujisawa,
  • Hideaki Nakajima

摘要

Purpose

This study aimed to develop and validate a personalized prognostic model for patients with newly diagnosed with acute myeloid leukemia (AML) receiving intensive cytarabine- and anthracycline-based chemotherapy.

Methods

 We retrospectively analyzed 161 patients treated at a single center and externally validated the model in 184 patients from two institutions.

Results

Using LASSO Cox regression, nine readily available clinical variables (age, sex, performance status, history of diabetes, respiratory disease, prior myelodysplastic syndrome or myeloproliferative neoplasm, serum albumin level, uric acid level, and adverse cytogenetic risk) were selected to construct a nomogram. The model demonstrated good discrimination of overall survival, with a concordance index of 0.721 and 0.678 in the training and validation cohorts, respectively. Calibration plots showed strong agreement between the predicted and observed outcomes. Based on the nomogram scores, the patients were stratified into three risk groups, with 3-year overall survival rates of 84.1%, 57.2%, and 11.9% in the good, intermediate, and poor-risk groups, respectively. To enhance clinical accessibility, an online tool was developed for use in real-world settings.

Conclusion

This nomogram integrates disease- and patient-related factors and allows for individualized prognostic assessment. This may support clinical assessment through personalized risk evaluation in AML patients.